Takayasu arteritis (TAK) is a chronic systemic large vessel vasculitis characterized by damage to the aorta and its major branches. TAK primarily occurs in young women in Asia, with a male-to-female ratio of approximately 1:8 [1,2]. Constitutional symptoms of systemic inflammation and vascular complications are the major clinical manifestations of patients with TAK. Despite improved treatment strategies, the majority of patients experience relapses. It is generally accepted that TAK should be treated with immunosuppressive therapy to control acute disease flare and maintain remission [1,3-5].
